Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

[1] Smith IE(2004)A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial Ann Oncol 15 751-758

[2] A’Hern RP(2004)Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study Br J Cancer 90 2131-2134

[3] Coombes GA(1999)Docetaxel (Taxotere) administered in weekly schedules Semin Oncol 26 28-31

[4] Humphreys AC(1998)Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer J Clin Oncol 16 2164-2168

[5] Dent J(1999)Weekly administration of docetaxel (Taxotere): summary of clinical data Semin Oncol 26 19-24

[6] Rodwell S(1996)The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1843-1849

[7] Greco FA(2002)Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies J Clin Oncol 20 2616-2623

[8] Hainsworth JD(1998)Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013-1019

[9] Burris HA(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-41

[10] Erland JB(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216

[1] Smith IE(2004)A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial Ann Oncol 15 751-758

[2] A’Hern RP(2004)Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study Br J Cancer 90 2131-2134

[3] Coombes GA(1999)Docetaxel (Taxotere) administered in weekly schedules Semin Oncol 26 28-31

[4] Humphreys AC(1998)Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer J Clin Oncol 16 2164-2168

[5] Dent J(1999)Weekly administration of docetaxel (Taxotere): summary of clinical data Semin Oncol 26 19-24

[6] Rodwell S(1996)The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1843-1849

[7] Greco FA(2002)Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies J Clin Oncol 20 2616-2623

[8] Hainsworth JD(1998)Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013-1019

[9] Burris HA(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-41

[10] Erland JB(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216